{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:45:22Z","timestamp":1780616722033,"version":"3.54.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>Antiepileptic drugs are versatile drugs with the potential to be used in functional drug formulations with drug repurposing approaches. In the present review, we investigated the anticancer properties of antiepileptic drugs and interlinked cancer and epileptic pathways. Our focus was primarily on those drugs that have entered clinical trials with positive results and those that provided good results in preclinical studies. Many contributing factors make cancer therapy fail, like drug resistance, tumor heterogeneity, and cost; exploring all alternatives for efficient treatment is important. It is crucial to find new drug targets to find out new antitumor molecules from the already clinically validated and approved drugs utilizing drug repurposing methods. The advancements in genomics, proteomics, and other computational approaches speed up drug repurposing. This review summarizes the potential of antiepileptic drugs in different cancers and tumor progression in the brain. Valproic acid, oxcarbazepine, lacosamide, lamotrigine, and levetiracetam are the drugs that showed potential beneficial outcomes against different cancers. Antiepileptic drugs might be a good option for adjuvant cancer therapy, but there is a need to investigate further their efficacy in cancer therapy clinical trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s11033-023-08568-1","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T11:01:58Z","timestamp":1688727718000},"page":"7667-7680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The evidence for repurposing anti-epileptic drugs to target cancer"],"prefix":"10.1007","volume":"50","author":[{"given":"Mir","family":"Aroosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonaid Ahmad","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakeel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5164-1970","authenticated-orcid":false,"given":"Nafees","family":"Ahemad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0926-2790","authenticated-orcid":false,"given":"Sirajudheen","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"8568_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00213-8","volume":"2020 51","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, Huang C (2020) Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther 2020 51:1\u201325. https:\/\/doi.org\/10.1038\/s41392-020-00213-8","journal-title":"Signal Transduct Target Ther"},{"key":"8568_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9734279","volume":"2021","author":"A Alamri","year":"2021","unstructured":"Alamri A, Rauf A, Khalil AA, Alghamdi A, Alafnan A, Alshammari A, Alshammari F, Malik JA, Anwar S (2021) In Silico Screening of Marine Compounds as an Emerging and Promising Approach against Estrogen receptor alpha-positive breast Cancer. Biomed Res Int 2021:1\u20137. https:\/\/doi.org\/10.1155\/2021\/9734279","journal-title":"Biomed Res Int"},{"key":"8568_CR3","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c05821","author":"JA Malik","year":"2022","unstructured":"Malik JA, Ahmed S, Momin SS, Shaikh S, Alafnan A, Alanazi J, Hajaj M, Almermesh S, Anwar S (2022) Drug Repurposing: a New Hope in Drug Discovery for prostate Cancer. ACS Omega. https:\/\/doi.org\/10.1021\/acsomega.2c05821","journal-title":"ACS Omega"},{"key":"8568_CR4","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.3390\/MOLECULES27227668","volume":"27","author":"S Anwar","year":"2022","unstructured":"Anwar S, Malik JA, Ahmed S, Kameshwar VA, Alanazi J, Alamri A, Ahemad N (2022) Can Natural Products Targeting EMT serve as the future Anticancer therapeutics? Mol 2022 27:7668. https:\/\/doi.org\/10.3390\/MOLECULES27227668","journal-title":"Mol 2022"},{"key":"8568_CR5","doi-asserted-by":"publisher","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R et al (2022) PD-1 blockade in Mismatch Repair-Deficient, locally advanced rectal Cancer. N Engl J Med 1\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2201445","DOI":"10.1056\/NEJMoa2201445"},{"key":"8568_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.arcmed.2020.10.021","volume":"52","author":"D Ju\u00e1rez-L\u00f3pez","year":"2021","unstructured":"Ju\u00e1rez-L\u00f3pez D, Schcolnik-Cabrera A (2021) Drug Repurposing: considerations to surpass while re-directing Old Compounds for New Treatments. Arch Med Res 52:243\u2013251. https:\/\/doi.org\/10.1016\/j.arcmed.2020.10.021","journal-title":"Arch Med Res"},{"key":"8568_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41571-019-0313-2","volume":"17","author":"R Kurzrock","year":"2020","unstructured":"Kurzrock R, Kantarjian HM, Kesselheim AS, Sigal EV (2020) New drug approvals in oncology. Nat Rev Clin Oncol 17:140\u2013146. https:\/\/doi.org\/10.1038\/s41571-019-0313-2","journal-title":"Nat Rev Clin Oncol"},{"key":"8568_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2017.69","volume":"14","author":"P Pantziarka","year":"2017","unstructured":"Pantziarka P (2017) Scientific advice-is drug repurposing missing a trick? Nat Rev Clin Oncol 14:455\u2013456. https:\/\/doi.org\/10.1038\/nrclinonc.2017.69","journal-title":"Nat Rev Clin Oncol"},{"key":"8568_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2018","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C et al (2018) Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 18:41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168","journal-title":"Nat Rev Drug Discov"},{"key":"8568_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","volume":"12","author":"F Bertolini","year":"2015","unstructured":"Bertolini F, Sukhatme VP, Bouche G (2015) Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol 12:732\u2013742. https:\/\/doi.org\/10.1038\/nrclinonc.2015.169","journal-title":"Nat Rev Clin Oncol"},{"key":"8568_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo N (2016) Can you teach old drugs new tricks? Nature 534:314\u2013316. https:\/\/doi.org\/10.1038\/534314a","journal-title":"Nature"},{"key":"8568_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13163946","volume":"13","author":"L De Lellis","year":"2021","unstructured":"De Lellis L, Veschi S, Tinari N, Mokini Z, Carradori S, Brocco D, Florio R, Grassadonia A, Cama A (2021) Drug repurposing, an attractive strategy in pancreatic cancer treatment: preclinical and clinical updates. Cancers (Basel) 13:1\u201339. https:\/\/doi.org\/10.3390\/cancers13163946","journal-title":"Cancers (Basel)"},{"key":"8568_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/J.SEMCANCER.2019.09.012","volume":"68","author":"S Aggarwal","year":"2021","unstructured":"Aggarwal S, Verma SS, Aggarwal S, Gupta SC (2021) Drug repurposing for breast cancer therapy: old weapon for new battle. Semin Cancer Biol 68:8\u201320. https:\/\/doi.org\/10.1016\/J.SEMCANCER.2019.09.012","journal-title":"Semin Cancer Biol"},{"key":"8568_CR14","doi-asserted-by":"crossref","unstructured":"Thilakasiri PS, Dmello RS, Nero TL, Parker MW, Ernst M, Chand AL (2021) Repurposing of drugs as STAT3 inhibitors for cancer therapy; Elsevier Ltd, ; Vol. 68; ISBN 0000016861","DOI":"10.1016\/j.semcancer.2019.09.022"},{"key":"8568_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00280-020-04216-8","volume":"87","author":"C Lu","year":"2021","unstructured":"Lu C, Li X, Ren Y, Zhang X (2021) Disulfiram: a novel repurposed drug for cancer therapy. Cancer Chemother Pharmacol 87:159\u2013172. https:\/\/doi.org\/10.1007\/s00280-020-04216-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"8568_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","volume":"19","author":"A Huang","year":"2020","unstructured":"Huang A, Garraway LA, Ashworth A, Weber B (2020) Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov 19:23\u201338. https:\/\/doi.org\/10.1038\/s41573-019-0046-z","journal-title":"Nat Rev Drug Discov"},{"key":"8568_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/clpt.2012.236","volume":"93","author":"DC Swinney","year":"2013","unstructured":"Swinney DC (2013) Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin Pharmacol Ther 93:299\u2013301","journal-title":"Clin Pharmacol Ther"},{"key":"8568_CR18","doi-asserted-by":"publisher","unstructured":"Dallavalle S, Dobri\u010di\u0107 V, Lazzarato L, Gazzano E, Machuqueiro M, Pajeva I, Tsakovska I, Zidar N, Fruttero R (2020) Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist Updat 50. https:\/\/doi.org\/10.1016\/j.drup.2020.100682","DOI":"10.1016\/j.drup.2020.100682"},{"key":"8568_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd3913","volume":"12","author":"MN Patel","year":"2013","unstructured":"Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B (2013) Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 12:35\u201350. https:\/\/doi.org\/10.1038\/nrd3913","journal-title":"Nat Rev Drug Discov"},{"key":"8568_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.bbcan.2019.04.005","volume":"1871","author":"P Nowak-Sliwinska","year":"2019","unstructured":"Nowak-Sliwinska P, Scapozza L, Altaba AR (2019) Drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta - Rev Cancer 1871:434\u2013454. https:\/\/doi.org\/10.1016\/j.bbcan.2019.04.005","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"key":"8568_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2017.00273","volume":"7","author":"JJ Hernandez","year":"2017","unstructured":"Hernandez JJ, Pryszlak M, Smith L, Yanchus C, Kurji N, Shahani VM, Molinski SV (2017) Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol 7:1\u20138. https:\/\/doi.org\/10.3389\/fonc.2017.00273","journal-title":"Front Oncol"},{"key":"8568_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"AL Hopkins","year":"2008","unstructured":"Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4:682\u2013690. https:\/\/doi.org\/10.1038\/nchembio.118","journal-title":"Nat Chem Biol"},{"key":"8568_CR23","doi-asserted-by":"publisher","unstructured":"Shinde SS, Ahmed S, Malik JA, Hani U, Khanam A, Ashraf Bhat F, Ahmad Mir S, Ghazwani M, Wahab S, Haider N et al (2023) Therapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment. Biol Vol.\u00a012, Page 467 2023, 12, 467, https:\/\/doi.org\/10.3390\/BIOLOGY12030467","DOI":"10.3390\/BIOLOGY12030467"},{"key":"8568_CR24","doi-asserted-by":"publisher","first-page":"2200407","DOI":"10.1002\/ARDP.202200407","volume":"356","author":"O Bender","year":"2023","unstructured":"Bender O, Shoman ME, Ali TFS, Dogan R, Celik I, Mollica A, Hamed MIA, Aly OM, Alamri A, Alanazi J et al (2023) Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation. Arch Pharm (Weinheim) 356:2200407. https:\/\/doi.org\/10.1002\/ARDP.202200407","journal-title":"Arch Pharm (Weinheim)"},{"key":"8568_CR25","doi-asserted-by":"publisher","unstructured":"Malik JA, Ahmed S, Jan B, Bender O, Al Hagbani T, Alqarni A, Anwar S Drugs repurposed: an advanced step towards the treatment of breast cancer and associated challenges. Biomed Pharmacother 145, 112375, https:\/\/doi.org\/10.1016\/J.BIOPHA.2021.112375","DOI":"10.1016\/J.BIOPHA.2021.112375"},{"key":"8568_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM (2019) A view on drug resistance in cancer. Nature 575:299\u2013309. https:\/\/doi.org\/10.1038\/s41586-019-1730-1","journal-title":"Nature"},{"key":"8568_CR27","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"CN Sternberg","year":"2001","unstructured":"Sternberg CN, De Mulder PHM, Schornagel JH, Th\u00e9odore C, Fossa SD, Van Oosterom AT, Witjes F, Spina M, Van Groeningen CJ, De Balincourt C et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: european organ. J Clin Oncol 19:2638\u20132646. https:\/\/doi.org\/10.1200\/JCO.2001.19.10.2638","journal-title":"J Clin Oncol"},{"key":"8568_CR28","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and leukemia. J Clin Oncol 21:1431\u20131439. https:\/\/doi.org\/10.1200\/JCO.2003.09.081","journal-title":"J Clin Oncol"},{"key":"8568_CR29","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/J.CELL.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of Cancer: the Next Generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/J.CELL.2011.02.013","journal-title":"Cell"},{"key":"8568_CR30","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Sci (80-) 359:1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Sci (80-)"},{"key":"8568_CR31","doi-asserted-by":"publisher","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U. S. A. 99, 12293\u201312297, https:\/\/doi.org\/10.1073\/pnas.192461099","DOI":"10.1073\/pnas.192461099"},{"key":"8568_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12026-009-8119-4","volume":"46","author":"SO Gollnick","year":"2010","unstructured":"Gollnick SO, Brackett CM (2010) Enhancement of antitumor immunity by photodynamic therapy. Immunol Res 46:216\u2013226. https:\/\/doi.org\/10.1007\/s12026-009-8119-4","journal-title":"Immunol Res"},{"key":"8568_CR33","first-page":"251","volume":"107","author":"G Stucchi","year":"2016","unstructured":"Stucchi G, Battevi N, Cairoli S, Consonni D (2016) The prevalence of musculoskeletal disorders in the retail sector: an italian cross sectional study on 3380 workers. Med Lav 107:251\u2013262","journal-title":"Med Lav"},{"key":"8568_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.18433\/j30c7d","volume":"14","author":"M Chidambaram","year":"2011","unstructured":"Chidambaram M, Manavalan R, Kathiresan K (2011) Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci a Publ Can Soc Pharm Sci Soc Can des Sci Pharm 14:67\u201377. https:\/\/doi.org\/10.18433\/j30c7d","journal-title":"J Pharm Pharm Sci a Publ Can Soc Pharm Sci Soc Can des Sci Pharm"},{"key":"8568_CR35","doi-asserted-by":"crossref","unstructured":"Bikiaris D, Papageorgiou G, Stergiou A, acta EP-T (2005) ; undefined Physicochemical studies on solid dispersions of poorly water-soluble drugs: evaluation of capabilities and limitations of thermal analysis techniques. Elsevier","DOI":"10.1016\/j.tca.2005.09.011"},{"key":"8568_CR36","doi-asserted-by":"publisher","unstructured":"Gote V, Nookala AR, Bolla PK, Pal D (2021) Drug resistance in metastatic breast cancer: Tumor targeted nanomedicine to the rescue. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22094673","DOI":"10.3390\/ijms22094673"},{"key":"8568_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.576559","volume":"10","author":"AP-Glycoprotein Seelig","year":"2020","unstructured":"Seelig AP-Glycoprotein (2020) One mechanism, many tasks and the Consequences for Pharmacotherapy of Cancers. Front Oncol 10:1\u201316","journal-title":"Front Oncol"},{"key":"8568_CR38","doi-asserted-by":"publisher","first-page":"84559","DOI":"10.18632\/oncotarget.19187","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang J, Seebacher N, Shi H, Kan Q, Duan Z (2017) Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget 8:84559\u201384571. https:\/\/doi.org\/10.18632\/oncotarget.19187","journal-title":"Oncotarget"},{"key":"8568_CR39","doi-asserted-by":"publisher","unstructured":"Bukowski K, Kciuk M, Kontek R (2020) Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21093233","DOI":"10.3390\/ijms21093233"},{"key":"8568_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","volume":"370","author":"Z Chen","year":"2016","unstructured":"Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L, Li J (2016) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett 370:153\u2013164. https:\/\/doi.org\/10.1016\/j.canlet.2015.10.010","journal-title":"Cancer Lett"},{"key":"8568_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0169-409X(02)00175-8","volume":"55","author":"AH Dantzig","year":"2003","unstructured":"Dantzig AH, De Alwis DP, Burgess M (2003) Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 55:133\u2013150. https:\/\/doi.org\/10.1016\/S0169-409X(02)00175-8","journal-title":"Adv Drug Deliv Rev"},{"key":"8568_CR42","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.2174\/092986712800167392","volume":"19","author":"A Palmeira","year":"2012","unstructured":"Palmeira A, Sousa E, Vasconcelos H, Pinto MM (2012) Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 19:1946\u20132025. https:\/\/doi.org\/10.2174\/092986712800167392","journal-title":"Curr Med Chem"},{"key":"8568_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","volume":"35","author":"M Nikolaou","year":"2018","unstructured":"Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E (2018) The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis 35:309\u2013318. https:\/\/doi.org\/10.1007\/s10585-018-9903-0","journal-title":"Clin Exp Metastasis"},{"key":"8568_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10555-007-9042-6","volume":"26","author":"RW Robey","year":"2007","unstructured":"Robey RW, Polgar O, Deeken J, To KW, Bates SE (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26:39\u201357. https:\/\/doi.org\/10.1007\/s10555-007-9042-6","journal-title":"Cancer Metastasis Rev"},{"key":"8568_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48\u201358. https:\/\/doi.org\/10.1038\/nrc706","journal-title":"Nat Rev Cancer"},{"key":"8568_CR46","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1360704","volume":"258","author":"SPC Cole","year":"1992","unstructured":"Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Sci (80-) 258:1650\u20131654. https:\/\/doi.org\/10.1126\/science.1360704","journal-title":"Sci (80-)"},{"key":"8568_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5732\/cjc.011.10329","volume":"31","author":"K Sodani","year":"2012","unstructured":"Sodani K, Patel A, Kathawala RJ, Chen ZS (2012) Multidrug resistance associated proteins in multindrung resistance. Chin J Cancer 31:58\u201372. https:\/\/doi.org\/10.5732\/cjc.011.10329","journal-title":"Chin J Cancer"},{"key":"8568_CR48","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","volume":"72","author":"T Haider","year":"2020","unstructured":"Haider T, Pandey V, Banjare N, Gupta PN, Soni V (2020) Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep 72:1125\u20131151. https:\/\/doi.org\/10.1007\/s43440-020-00138-7","journal-title":"Pharmacol Rep"},{"key":"8568_CR49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.canlet.2015.07.044","volume":"380","author":"Y Sun","year":"2016","unstructured":"Sun Y (2016) Tumor microenvironment and cancer therapy resistance. Cancer Lett 380:205\u2013215. https:\/\/doi.org\/10.1016\/j.canlet.2015.07.044","journal-title":"Cancer Lett"},{"key":"8568_CR50","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1039\/c8cs00304a","volume":"48","author":"A Sharma","year":"2019","unstructured":"Sharma A, Arambula JF, Koo S, Kumar R, Singh H, Sessler JL, Kim JS (2019) Hypoxia-targeted drug delivery. Chem Soc Rev 48:771\u2013813. https:\/\/doi.org\/10.1039\/c8cs00304a","journal-title":"Chem Soc Rev"},{"key":"8568_CR51","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/2159-8290.CD-15-0748","volume":"5","author":"EL Kwak","year":"2015","unstructured":"Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Godfrey JT, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, John Iafrate A et al (2015) Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-Amplified esophagogastric cancer. Cancer Discov 5:1271\u20131281. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0748","journal-title":"Cancer Discov"},{"key":"8568_CR52","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.3892\/mmr.2014.3058","volume":"11","author":"BX Zhao","year":"2015","unstructured":"Zhao BX, Wang J, Song B, Wei H, Lv WP, Tian LM, Li M, Lv S (2015) Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975\/gefinitib-resistant with epidermal growth factor receptor T790M mutation. Mol Med Rep 11:2767\u20132774. https:\/\/doi.org\/10.3892\/mmr.2014.3058","journal-title":"Mol Med Rep"},{"key":"8568_CR53","doi-asserted-by":"publisher","first-page":"pagerange","DOI":"10.1016\/j.bbadis.2018.11.015","volume":"1866","author":"MR Makena","year":"2020","unstructured":"Makena MR, Ranjan A, Thirumala V, Reddy AP (2020) Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance. Biochim Biophys Acta - Mol Basis Dis 1866:pagerange. https:\/\/doi.org\/10.1016\/j.bbadis.2018.11.015","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"key":"8568_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-38672-x","volume":"9","author":"C Chandrasekhar","year":"2019","unstructured":"Chandrasekhar C, Kumar PS, Sarma PVGK (2019) Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. Sci Rep 9:1\u201317. https:\/\/doi.org\/10.1038\/s41598-019-38672-x","journal-title":"Sci Rep"},{"key":"8568_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12878-019-0139-2","volume":"19","author":"G Greenfield","year":"2019","unstructured":"Greenfield G, McMullan R, Robson N, McGimpsey J, Catherwood M, McMullin MF (2019) Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia. BMC Hematol 19:1\u20139. https:\/\/doi.org\/10.1186\/s12878-019-0139-2","journal-title":"BMC Hematol"},{"key":"8568_CR56","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/nar\/gky072","volume":"46","author":"LI Lara","year":"2018","unstructured":"Lara LI, Fenner S, Ratcliffe S, Isidro-Llobet A, Hann M, Bax B, Osheroff N (2018) Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences. Nucleic Acids Res 46:2218\u20132233. https:\/\/doi.org\/10.1093\/nar\/gky072","journal-title":"Nucleic Acids Res"},{"key":"8568_CR57","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1399-0004.2011.01809.x","volume":"81","author":"R Kanwal","year":"2012","unstructured":"Kanwal R, Gupta S (2012) Epigenetic modifications in cancer. Clin Genet 81:303\u2013311. https:\/\/doi.org\/10.1111\/j.1399-0004.2011.01809.x","journal-title":"Clin Genet"},{"key":"8568_CR58","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","volume":"25","author":"HP Mohammad","year":"2019","unstructured":"Mohammad HP, Barbash O, Creasy CL (2019) Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med 25:403\u2013418. https:\/\/doi.org\/10.1038\/s41591-019-0376-8","journal-title":"Nat Med"},{"key":"8568_CR59","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrc3342","volume":"12","author":"P Bouwman","year":"2012","unstructured":"Bouwman P, Jonkers J (2012) The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 12:587\u2013598. https:\/\/doi.org\/10.1038\/nrc3342","journal-title":"Nat Rev Cancer"},{"key":"8568_CR60","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714\u2013726. https:\/\/doi.org\/10.1038\/nrc3599","journal-title":"Nat Rev Cancer"},{"key":"8568_CR61","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860\u2013867. https:\/\/doi.org\/10.1038\/nature01322","journal-title":"Nature"},{"key":"8568_CR62","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.tins.2007.08.007","volume":"30","author":"K Biber","year":"2007","unstructured":"Biber K, Neumann H, Inoue K, Boddeke HWGM (2007) Neuronal \u201cOn\u201d and \u201cOff\u201d signals control microglia. Trends Neurosci 30:596\u2013602. https:\/\/doi.org\/10.1016\/j.tins.2007.08.007","journal-title":"Trends Neurosci"},{"key":"8568_CR63","doi-asserted-by":"publisher","first-page":"104786","DOI":"10.1016\/j.phrs.2020.104786","volume":"156","author":"F Cucchiara","year":"2020","unstructured":"Cucchiara F, Pasqualetti F, Giorgi FS, Danesi R, Bocci G (2020) Epileptogenesis and oncogenesis: an antineoplastic role for antiepileptic drugs in brain tumours? Pharmacol Res 156:104786. https:\/\/doi.org\/10.1016\/j.phrs.2020.104786","journal-title":"Pharmacol Res"},{"key":"8568_CR64","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00702-014-1182-6","volume":"121","author":"A Stepulak","year":"2014","unstructured":"Stepulak A, Rola R, Polberg K, Ikonomidou C (2014) Glutamate and its receptors in cancer. J Neural Transm 121:933\u2013944. https:\/\/doi.org\/10.1007\/s00702-014-1182-6","journal-title":"J Neural Transm"},{"key":"8568_CR65","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/wmts.21","volume":"1","author":"J Teh","year":"2012","unstructured":"Teh J, Chen S (2012) Metabotropic glutamate receptors and cancerous growth. Wiley Interdiscip Rev Membr Transp Signal 1:211\u2013220. https:\/\/doi.org\/10.1002\/wmts.21","journal-title":"Wiley Interdiscip Rev Membr Transp Signal"},{"key":"8568_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1152\/physiol.00002.2009","volume":"24","author":"SZ Young","year":"2009","unstructured":"Young SZ, Bordey A (2009) GABA\u2019s control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology 24:171\u2013185. https:\/\/doi.org\/10.1152\/physiol.00002.2009","journal-title":"Physiology"},{"key":"8568_CR67","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/BF01294790","volume":"96","author":"A Jussofie","year":"1994","unstructured":"Jussofie A, Reinhardt V, Kalff R (1994) GABA binding sites: their density, their affinity to muscimol and their behaviour against neuroactive steroids in human gliomas of different degrees of malignancy. J Neural Transm 96:233\u2013241. https:\/\/doi.org\/10.1007\/BF01294790","journal-title":"J Neural Transm"},{"key":"8568_CR68","doi-asserted-by":"publisher","unstructured":"Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM, Li H, Hambrecht AC, Roberts E, Jandial R (2014) Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc. Natl. Acad. Sci. U. S. A. 111, 984\u2013989, https:\/\/doi.org\/10.1073\/pnas.1322098111","DOI":"10.1073\/pnas.1322098111"},{"key":"8568_CR69","doi-asserted-by":"publisher","unstructured":"Ludewig F, H\u00fcser A, Fromm H, Beauclair L, Bouch\u00e9 N (2008) Mutants of GABA transaminase (POP2) suppress the severe phenotype of succinic semialdehyde dehydrogenase (ssadh) mutants in arabidopsis. PLoS ONE 3. https:\/\/doi.org\/10.1371\/journal.pone.0003383","DOI":"10.1371\/journal.pone.0003383"},{"key":"8568_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms17091513","volume":"17","author":"L Klumpp","year":"2016","unstructured":"Klumpp L, Sezgin EC, Eckert F, Huber SM (2016) Ion channels in brain metastasis. Int J Mol Sci 17:1\u201314. https:\/\/doi.org\/10.3390\/ijms17091513","journal-title":"Int J Mol Sci"},{"key":"8568_CR71","doi-asserted-by":"publisher","unstructured":"Molenaar RJ (2011) Ion Channels in Glioblastoma. ISRN Neurol. 2011, 1\u20137, https:\/\/doi.org\/10.5402\/2011\/590249","DOI":"10.5402\/2011\/590249"},{"key":"8568_CR72","doi-asserted-by":"publisher","unstructured":"Becchetti A (2011) Ion channels and transporters in cancer. 1. Ion channels and cell proliferationin cancer. Am J Physiol - Cell Physiol 301. https:\/\/doi.org\/10.1152\/ajpcell.00047.2011","DOI":"10.1152\/ajpcell.00047.2011"},{"key":"8568_CR73","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00232-005-0781-4","volume":"205","author":"K Kunzelmann","year":"2005","unstructured":"Kunzelmann K (2005) Ion channels and cancer. J Membr Biol 205:159\u2013173. https:\/\/doi.org\/10.1007\/s00232-005-0781-4","journal-title":"J Membr Biol"},{"key":"8568_CR74","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.tins.2012.05.001","volume":"35","author":"S Watkins","year":"2012","unstructured":"Watkins S, Sontheimer H (2012) Unique biology of gliomas: Challenges and opportunities. Trends Neurosci 35:546\u2013556. https:\/\/doi.org\/10.1016\/j.tins.2012.05.001","journal-title":"Trends Neurosci"},{"key":"8568_CR75","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41577-018-0051-1.Interplay","volume":"176","author":"X Li","year":"2016","unstructured":"Li X, \u4e73\u9f20\u5fc3\u808c\u63d0\u53d6 HHS, Access P (2016) Physiol Behav 176:139\u2013148. https:\/\/doi.org\/10.1038\/s41577-018-0051-1.Interplay","journal-title":"Physiol Behav"},{"key":"8568_CR76","doi-asserted-by":"publisher","unstructured":"Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure Prognosis in Brain Tumors: New Insights and Evidence-Based Management. Oncologist 19, 751\u2013759, https:\/\/doi.org\/10.1634\/theoncologist.2014-0060","DOI":"10.1634\/theoncologist.2014-0060"},{"key":"8568_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ane.12437","volume":"133","author":"HA Gefroh-Grimes","year":"2016","unstructured":"Gefroh-Grimes HA, Gidal BE (2016) Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. Acta Neurol Scand 133:4\u201316. https:\/\/doi.org\/10.1111\/ane.12437","journal-title":"Acta Neurol Scand"},{"key":"8568_CR78","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","volume":"34","author":"A Duenas-Gonzalez","year":"2008","unstructured":"Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206\u2013222. https:\/\/doi.org\/10.1016\/j.ctrv.2007.11.003","journal-title":"Cancer Treat Rev"},{"key":"8568_CR79","doi-asserted-by":"crossref","unstructured":"Englot DJ, Chang EF, Vecht CJ (2016) Epilepsy and brain tumors; 1st ed.; Elsevier B.V., ; Vol. 134; ISBN 9780128029978","DOI":"10.1016\/B978-0-12-802997-8.00016-5"},{"key":"8568_CR80","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher M, Minucci S, Zhu P, Kr\u00e4mer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969\u20136978. https:\/\/doi.org\/10.1093\/emboj\/20.24.6969","journal-title":"EMBO J"},{"key":"8568_CR81","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/cncr.22891","volume":"110","author":"A Kuendgen","year":"2007","unstructured":"Kuendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancies. Cancer 110:943\u2013954. https:\/\/doi.org\/10.1002\/cncr.22891","journal-title":"Cancer"},{"key":"8568_CR82","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.leukres.2011.02.021","volume":"35","author":"MT Corsetti","year":"2011","unstructured":"Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F et al (2011) Hematologic improvement and response in elderly AML\/RAEB patients treated with valproic acid and low-dose Ara-C. Leuk Res 35:991\u2013997. https:\/\/doi.org\/10.1016\/j.leukres.2011.02.021","journal-title":"Leuk Res"},{"key":"8568_CR83","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.radonc.2015.10.009","volume":"117","author":"JP Reddy","year":"2015","unstructured":"Reddy JP, Dawood S, Mitchell M, Debeb BG, Bloom E, Gonzalez-Angulo AM, Sulman EP, Buchholz TA, Woodward WA (2015) Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. Radiother Oncol 117:308\u2013314. https:\/\/doi.org\/10.1016\/j.radonc.2015.10.009","journal-title":"Radiother Oncol"},{"key":"8568_CR84","doi-asserted-by":"publisher","unstructured":"Mackenzie GG, Huang L, Alston N, Ouyang N, Vrankova K, Mattheolabakis G, Constantinides PP, Rigas B (2013) Targeting mitochondrial STAT3 with the Novel Phospho-Valproic acid (MDC-1112) inhibits pancreatic Cancer growth in mice. PLoS ONE 8. https:\/\/doi.org\/10.1371\/journal.pone.0061532","DOI":"10.1371\/journal.pone.0061532"},{"key":"8568_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13143409","volume":"13","author":"A Wawruszak","year":"2021","unstructured":"Wawruszak A, Halasa M, Okon E, Kukula-Koch W, Stepulak A (2021) Valproic acid and breast cancer: state of the art in 2021. Cancers (Basel) 13:1\u201323. https:\/\/doi.org\/10.3390\/cancers13143409","journal-title":"Cancers (Basel)"},{"key":"8568_CR86","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/J.TOXLET.2021.07.018","volume":"350","author":"M Ota","year":"2021","unstructured":"Ota M, Funakoshi T, Aki T, Unuma K, Uemura K (2021) Oxcarbazepine induces mitotic catastrophe and apoptosis in NRK-52E proximal tubular cells. Toxicol Lett 350:240\u2013248. https:\/\/doi.org\/10.1016\/J.TOXLET.2021.07.018","journal-title":"Toxicol Lett"},{"key":"8568_CR87","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7314\/APJCP.2014.15.1.199","volume":"15","author":"FZ El Sharkawi","year":"2014","unstructured":"El Sharkawi FZ, El Shemy HA, Khaled HM (2014) Possible anticancer activity of rosuvastatine, doxazosin, repaglinide and oxcarbazepin. Asian Pac J Cancer Prev 15:199\u2013203. https:\/\/doi.org\/10.7314\/APJCP.2014.15.1.199","journal-title":"Asian Pac J Cancer Prev"},{"key":"8568_CR88","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.seizure.2010.11.019","volume":"20","author":"A Cansu","year":"2011","unstructured":"Cansu A, Ekinci \u00d6, Serdaroglu A, G\u00fcrgen SG, Ekinci \u00d6, Erdogan D, Coskun ZK, Tunc L (2011) Effects of chronic treatment with valproate and oxcarbazepine on testicular development in rats. Seizure 20:203\u2013207. https:\/\/doi.org\/10.1016\/j.seizure.2010.11.019","journal-title":"Seizure"},{"key":"8568_CR89","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/WNF.0000000000000218","volume":"40","author":"M Maschio","year":"2017","unstructured":"Maschio M, Dinapoli L, Zarabla A, Maialetti A, Giannarelli D, Fabi A, Vidiri A, Cantelmi T (2017) Zonisamide in brain tumor-related epilepsy: an observational pilot study. Clin Neuropharmacol 40:113\u2013119. https:\/\/doi.org\/10.1097\/WNF.0000000000000218","journal-title":"Clin Neuropharmacol"},{"key":"8568_CR90","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11060-016-2056-6","volume":"127","author":"CY Lee","year":"2016","unstructured":"Lee CY, Lai HY, Chiu A, Chan SH, Hsiao LP, Lee ST (2016) The effects of antiepileptic drugs on the growth of glioblastoma cell lines. J Neurooncol 127:445\u2013453. https:\/\/doi.org\/10.1007\/s11060-016-2056-6","journal-title":"J Neurooncol"},{"key":"8568_CR91","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/mol.107.039867","volume":"73","author":"AC Errington","year":"2008","unstructured":"Errington AC, St\u00f6hr T, Heers C, Lees G (2008) The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 73:157\u2013169. https:\/\/doi.org\/10.1124\/mol.107.039867","journal-title":"Mol Pharmacol"},{"key":"8568_CR92","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3171\/2013.1.JNS12397","volume":"118","author":"MG Saria","year":"2013","unstructured":"Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Fu BD, Kim RY et al (2013) Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors. J Neurosurg 118:1183\u20131187. https:\/\/doi.org\/10.3171\/2013.1.JNS12397","journal-title":"J Neurosurg"},{"key":"8568_CR93","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yebeh.2017.05.031","volume":"73","author":"M Maschio","year":"2017","unstructured":"Maschio M, Zarabla A, Maialetti A, Fabi A, Vidiri A, Villani V, Giannarelli D (2017) Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group. Epilepsy Behav 73:83\u201389. https:\/\/doi.org\/10.1016\/j.yebeh.2017.05.031","journal-title":"Epilepsy Behav"},{"key":"8568_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pbb.2015.04.011","volume":"134","author":"SR Bang","year":"2015","unstructured":"Bang SR, Ambavade SD, Jagdale PG, Adkar PP, Waghmare AB, Ambavade PD (2015) Lacosamide reduces HDAC levels in the brain and improves memory: potential for treatment of Alzheimer\u2019s disease. Pharmacol Biochem Behav 134:65\u201369. https:\/\/doi.org\/10.1016\/j.pbb.2015.04.011","journal-title":"Pharmacol Biochem Behav"},{"key":"8568_CR95","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/cancers5041306","volume":"5","author":"M Li","year":"2013","unstructured":"Li M, Li J, Liu L, Li W, Yang Y, Yuan J (2013) MicroRNA in human glioma. Cancers (Basel) 5:1306\u20131331. https:\/\/doi.org\/10.3390\/cancers5041306","journal-title":"Cancers (Basel)"},{"key":"8568_CR96","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1007\/s12035-017-0653-9","volume":"55","author":"A Moutal","year":"2018","unstructured":"Moutal A, Villa LS, Yeon SK, Householder KT, Park KD, Sirianni RW, Khanna R (2018) CRMP2 phosphorylation drives Glioblastoma Cell Proliferation. Mol Neurobiol 55:4403\u20134416. https:\/\/doi.org\/10.1007\/s12035-017-0653-9","journal-title":"Mol Neurobiol"},{"key":"8568_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13046-017-0546-9\/FIGURES\/6","volume":"36","author":"A Rizzo","year":"2017","unstructured":"Rizzo A, Donzelli S, Girgenti V, Sacconi A, Vasco C, Salmaggi A, Blandino G, Maschio M, Ciusani E (2017) In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. J Exp Clin Cancer Res 36:1\u201313. https:\/\/doi.org\/10.1186\/S13046-017-0546-9\/FIGURES\/6","journal-title":"J Exp Clin Cancer Res"},{"key":"8568_CR98","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cam4.4454","volume":"11","author":"K Hwang","year":"2022","unstructured":"Hwang K, Kim J, Kang SG, Jung TY, Kim JH, Kim SH, Kang SH, Hong YK, Kim TM, Kim YJ et al (2022) Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: an open-label phase 2 study. Cancer Med 11:371\u2013379. https:\/\/doi.org\/10.1002\/cam4.4454","journal-title":"Cancer Med"},{"key":"8568_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-018-0626-8","volume":"18","author":"BM Scicchitano","year":"2018","unstructured":"Scicchitano BM, Sorrentino S, Proietti G, Lama G, Dobrowolny G, Catizone A, Binda E, Larocca LM, Sica G (2018) Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int 18:1\u201318. https:\/\/doi.org\/10.1186\/s12935-018-0626-8","journal-title":"Cancer Cell Int"},{"key":"8568_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep25705","volume":"6","author":"JFM Manchon","year":"2016","unstructured":"Manchon JFM, Dabaghian Y, Uzor NE, Kesler SR, Wefel JS, Tsvetkov AS (2016) Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Sci Rep 6:1\u201312. https:\/\/doi.org\/10.1038\/srep25705","journal-title":"Sci Rep"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08568-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08568-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08568-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T05:02:34Z","timestamp":1693112554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08568-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["8568"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08568-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"22 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}